Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. On-demand manufacturing of clinical-quality biopharmaceuticals

On-demand manufacturing of clinical-quality biopharmaceuticals

Thumbnail Image
Name

nihms-1505042.pdf

Description
Accepted version
Size

2.05 MB

Format

Adobe PDF

Checksum (MD5)

d2d778103270ecfad644806819070e8a

sword-2019-08-14T18:38:22.original.xml (130 B)
Original SWORD entry document
Author(s)
Crowell, Laura E
•
Lu, Amos E
•
Love, Kerry R
•
Stockdale, Alan
•
Timmick, Steven M
•
Wu, Di
•
Wang, Yu Annie
•
Doherty, William
•
Bonnyman, Alexandra
•
Vecchiarello, Nicholas
more
Date Issued
2018
Journal
Nature Biotechnology
Publisher
Springer Science and Business Media LLC
Version
Author's final manuscript
Abstract
© 2018, Nature Publishing Group. All rights reserved. Conventional manufacturing of protein biopharmaceuticals in centralized, large-scale, single-product facilities is not well-suited to the agile production of drugs for small patient populations or individuals. Previous solutions for small-scale manufacturing are limited in both process reproducibility and product quality, owing to their complicated means of protein expression and purification1–4. We describe an automated, benchtop, multiproduct manufacturing system, called Integrated Scalable Cyto-Technology (InSCyT), for the end-to-end production of hundreds to thousands of doses of clinical-quality protein biologics in about 3 d. Unlike previous systems, InSCyT includes fully integrated modules for sustained production, efficient purification without the use of affinity tags, and formulation to a final dosage form of recombinant biopharmaceuticals. We demonstrate that InSCyT can accelerate process development from sequence to purified drug in 12 weeks. We used integrated design to produce human growth hormone, interferon a-2b and granulocyte colony-stimulating factor with highly similar processes on this system and show that their purity and potency are comparable to those of marketed reference products.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/134719
DOI of Published Version
10.1038/NBT.4262
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.